Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 0.74 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.74 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.74 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14538756 | 0.88 | SLC6A4 (0.76) | SLC6A4SLC6A2OPRM1SLC22A1OPRD1 | |
| SCHEMBL5411927 | 0.87 | SLC6A4 (0.74) | SLC6A4SLC6A2OPRM1SLC22A1OPRD1 | |
| SCHEMBL29427228 | 0.87 | SLC6A4 (0.74) | SLC6A4SLC6A2OPRM1SLC22A1OPRD1 | |
| SCHEMBL13007830 | 0.87 | SLC6A4 (0.74) | SLC6A4SLC6A2OPRM1SLC22A1OPRD1 | |
| (R,R)-Tramadol SCHEMBL5318670 | 0.85 | SLC6A2 (1.00) | SLC6A4SLC6A2OPRM1SLC22A1OPRD1 | |
| (R,R)-Tramadol SCHEMBL11984200 | 0.85 | SLC6A2 (1.00) | SLC6A4SLC6A2OPRM1SLC22A1OPRD1 | |
| (R,R)-Tramadol SCHEMBL3265792 | 0.85 | SLC6A2 (1.00) | SLC6A4SLC6A2OPRM1SLC22A1OPRD1 | |
| SCHEMBL4393885 | 0.85 | SLC22A1 (1.00) | SLC6A4SLC6A2OPRM1SLC22A1OPRD1 | |
| (R,R)-Tramadol SCHEMBL57495 | 0.85 | SLC6A2 (1.00) | SLC6A4SLC6A2OPRM1SLC22A1OPRD1 | |
| (R,R)-Tramadol SCHEMBL12831358 | 0.85 | SLC6A2 (1.00) | SLC6A4SLC6A2OPRM1SLC22A1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088918-B2 | Noncardiotoxic pharmaceutical compounds | WILLIAMSBURG HOLDINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-20060035863-A1 | Noncardiotoxic pharmaceutical compounds | B&G PARTNERS, LLC | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035863-A1 | Noncardiotoxic pharmaceutical compounds | KCNN3, TNNI3, TNNT2 | SLC6A4 380/4885SLC6A2 1062/4885OPRM1 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.